Inclusion Criteria:

1. Histologically confirmed de novo diffuse large B-cell lymphoma or follicular lymphoma
grade 3B

2. Age>=16 y.o.,<=80 y.o.

3. ECOG < 3

4. No past history of malignancy

5. Radiologically measurable disease, CT imaging in screening showing 2 or more clearly
demarcated lesions with a largest diameter > 1.5 cm, or 1 clearly demarcated lesion
with a largest diameter > 2.0 cm.

6. Life expectancy>6 months

7. Informed consented

Exclusion Criteria:

1. Chemotherapy before

2. Bone marrow transplantation before

3. History of malignancy

4. Active infectious disease requiring general antibiotics, anti-fungal or anti-virus
therapy

5. Uncontrollable cardio-cerebral vascular, coagulative, autoimmune, serious infectious
disease

6. Primary cutaneous, CNS, mediastinal DLBCL

7. LVEF≤50%

8. Other uncontrollable medical condition that may that may interfere the participation
of the study

9. Lab at enrollment(unless caused by lymphoma)

- Neutrophile<1.5*10^9/L

- Platelet<80*10^9/L

- Hemoglobulin<100g/L

- ALT or AST >2*ULN,AKP or bilirubin >1.5*ULN

- Creatinine>1.5*ULN

10. Not able to comply to the protocol for mental or other unknown reasons

11. Pregnant or lactation

12. Active liver or biliary disease

13. If HbsAg positive, should check HBV DNA, DNA positive patients cannot be enrolled. If
HBsAg negative but HBcAb positive (whatever HBsAb status), should check HBV DNA,DNA
positive patients cannot be enrolled.

14. HIV infection